Business Wire

Heritage Group Led by Manfredi Lefebvre Has Made a Major Investment in Return for a 75% Equity Interest in Bucksense Inc.

Share

Bucksense is a US service provider with offices in New York, Madrid, Rome, and Mumbai, featuring a programmatic platform for advertisers and agencies looking to bring brand building in house. Bucksense offers marketers control over media buying with a direct and simple interface. Bucksense’s Creative Suite is one of the world's first self-serve ad creative solutions that leverages programmatic data. Responsive ad formats enable users to take multiple paths (change topics, book appointments, opt-out, etc), all within the one ad unit, producing smart and self-learning campaigns.

“Programmatic has been a game changer in the online advertising and has drastically transformed for the better the way advertisers and publishers interact” Lefebvre said. “Programmatic Advertising” he continued “is an extremely powerful tool constantly evolving but all its facets maintain a common denominator: efficiency. At Silversea we have started to invest heavily in digital communication 6 years ago, with Silversea being one of the pioneers in the cruise industry and now our Holding company Heritage is making this investment as a reaffirmation of our firm belief that the digital world in which we live is a better world and can be even better with platforms like Bucksense that in full transparency meets the requirements of a more and more sophisticated clientele.”

Bucksense’s CEO and Founder, Cristian Carnevale, added “Bucksense was founded in 2012 because we saw a need for brands to take back control of their ads spend and quality. The fact that Heritage Group decided to financially support our endeavor, guarantees to me that Bucksense will quickly become a leading and revolutionary presence of the Programmatic Advertising industry."

Heritage Group is an investment company chaired by Manfredi Lefebvre that invests in several industries including, among others, travel, leisure & hospitality and other diversified businesses. Heritage transformed Silversea Cruises, the family company founded by Manfredi’s father in 1994, into the most successful luxury cruise line in the world with a global organization, a fleet of 9 ships and other 5 under construction/order. Heritage sold the majority stake of Silversea to Royal Caribbean in summer 2018 at an enterprise value of over 2 billion dollars and it recently reinvested part of the equity into the acquisition of 85% of what is undoubtedly considered the most valued luxury travel company in the world, Abercrombie and Kent.

Contact information

Adrian Rubio
adrian.rubio@bucksense.com
SVP, Corporate Development

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetMedia Group takes over the management of financial platform Investing.com's European advertising space23.7.2019 08:07:00 CESTPress release

NetMedia Group, media B2B leader in Europe in the world of business information, and Investing.com, second largest financial services and information platform in Europe, are to form a partnership, with NetMedia Group handling the sales of advertising space for Investing.com. With average traffic of over 21 million unique users totaling over 175 million sessions in 31 countries, Investing.com is one of the top three global financial websites and has the most downloaded financial management app. For Investing.com, the aim of the new partnership is to maximize digital advertising revenue through the NetMedia Group's European teams. NetMedia Group's goal is to expand its advertising services by offering a new vertical market for finance, in order to boost the range of services it has available to decision-makers for upper socio-professional target groups. About NetMedia Group: NetMedia Group is a B2B media group located in five countries across Europe; it employs nearly 150 staff members a

Frost & Sullivan Names Luminati the 2019 Global Market Leader in the Enterprise IP Proxy Networks Market23.7.2019 08:00:00 CESTPress release

Luminati, the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it has received a Market Leadership Award in the first independent analysis of the sector. Luminati’s enterprise IP proxy network (IPPN) services for global retailers, brand owners and advertising networks feature strongly in the report by analyst firm Frost & Sullivan. The report outlines a relatively new, but rapidly growing market and recognizes Luminati’s leading position in the provision of solutions that are increasingly important for businesses to remain competitive and compliant in the digital landscape. [S1] “The market for enterprise IP proxy network solutions is in its early growth stages, basically being invented by Luminati only a few years ago. With the more specialized targeting of customers by demographics and location, companies are finding it more difficult than ever to do competitive analysis and verify advertising,

LifeSpan BioSciences Releases Best-In-Class PathPlus™ Top Performing Immunohistochemistry Antibodies for Cancer Targets23.7.2019 08:00:00 CESTPress release

LifeSpan BioSciences, Inc. (LSBio™), the industry leader in molecular pathology, today announced the first release of its PathPlus™ series of antibodies. These 565 antibodies were selected from among thousands tested and identified to be the best performing reagents for immunohistochemical detection of 200 high-value cancer targets in formalin-fixed paraffin-embedded human tissues. Antibody validation has become an industry roadblock as thousands of antibodies have become available to customers who face difficult choices in determining which antibodies are the best performers for each application, including immunohistochemistry, flow cytometry, ELISA, Western blot, or immunofluorescence. Antibodies that perform well in one assay, such as IHC, may not be the most specific reagent for another assay, such as flow cytometry. “Identifying the optimal reagents to use in their experiments is a pain point for researchers,” said LSBio CEO Heather Holemon. “There is a tremendous need to identify

IDEMIA Will Present Its H1 2019 Financial Results to Investors on July 30, 201923.7.2019 07:00:00 CESTPress release

IDEMIA, the world leader in Augmented Identity, today announced that it will present its H1 2019 financial results to investors on Tuesday July 30, 2019. Yann Delabrière (CEO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 3:30 pm CET (2:30 pm London Time / 9:30 am New York Time). For more information, please refer to our website: https://investors.idemia.com/ About IDEMIA IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whet

Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CESTPress release

Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the

iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CESTPress release

iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g